Contact Us
© 2017 Pharmstandard Ventures

Archive News

Fund's News and Porfolio Companies' News

Archive News

Fund's News and Porfolio Companies' News
All News
Fund's News
Portfolio Companies' News
28.09.2018

Upcoming Events – 4Q 2018
26.03.2018

Upcoming Events – 2Q 2018
20.12.2017

Upcoming Events – 1Q 2018
07.12.2017

Pharmstandard International and Middleland Capital's VTC Innovation Fund Co-lead $8.5m Series B Financing of TearSolutions, Inc.
05.12.2017

Pharmstandard International Participated in Series B Extension Funding of Neon Therapeutics
29.09.2017

Upcoming Events – 2017
03.08.2017

Our Portfolio Company, Proteon Therapeutics Announces Closing of $22 Million Convertible Preferred Stock Financing
16.05.2014

Inbio Ventures Co-Leads Syndicated $45 Million Series D Investment in Proteon Therapeutics
30.08.2013

Inbio Ventures Represents Lead Investor in $42.5 Million Financing Round for Argos Therapeutics
12.08.2013

Inbio Ventures Joins the Syndicated $18 Million Investment in Protagonist Therapeutics
03.04.2013

Aquinox investment
18.12.2019
Neon Therapeutics Submits European Clinical Trial Authorization Application for Personal Neoantigen-Targeted T Cell Therapy NEO-PTC-01
04.12.2019
TransMedics' Organ Care System (OCS™) Technology Used in First U.S. Adult Human Heart Transplants From DCD Donors
04.12.2019
Allena Pharmaceuticals Provides Updates on Reloxaliase Development Program and Corporate Activities
03.12.2019
Protagonist Therapeutics Announces Preliminary Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Transfusion Dependent Beta-Thalassemia
22.11.2019
Avelas Welcomes Susan Stimson to its Board of Directors
20.11.2019
Neon Therapeutics Announces New Strategic Focus on Novel T Cell Programs
08.11.2019
Neon Therapeutics Announces Updated Data Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting
07.11.2019
Allena Pharmaceuticals Reports Positive Reloxaliase Topline Results from URIROX-1 Trial and from Study 206
06.11.2019
Protagonist Therapeutics Announces First Patient Dosed in a Phase 2 Study of Oral IL-23 Receptor Antagonist PTG-200 (JNJ-67864238) in the Treatment of Crohn's Disease
31.10.2019
Protagonist Therapeutics Secures Debt Facility for up to $50 Million
30.10.2019
Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Polycythemia Vera
23.09.2019
Proteon Therapeutics and ArTara Therapeutics Agree to Combine
17.09.2019
Jounce Therapeutics Names Jacquelyn Fahey Sandell as Chief Legal Officer and Corporate Secretary
16.09.2019
Allena Pharmaceuticals Completes Enrollment in Pivotal Phase 3 URIROX-1 Trial Evaluating Reloxaliase in Patients with Enteric Hyperoxaluria
05.09.2019
Neon Therapeutics Announces Publication in Immunity of Novel Approach to Predict MHC Class II Cancer-Specific Neoantigens
01.08.2019
Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Sustained Dose-Related Target Engagement Activity in a Multiple Ascending Dose Phase 1 Study
30.07.2019
TransMedics Announces Successful Long Distance Retrieval and Transplantation of Donor Lungs from Hawaii Using Organ Care System
23.07.2019
Jounce Therapeutics Announces Update on Strategic Collaboration with Celgene Corporation
15.07.2019
Neon Therapeutics' Personal Neoantigen Vaccine Study Demonstrates Prolonged Progression-Free Survival in Advanced or Metastatic Melanoma, Non-Small Cell Lung and Bladder Cancers
27.06.2019
Allena Pharmaceuticals Announces $10.0 Million Registered Direct Offering of Common Stock
18.06.2019
Jounce Therapeutics Initiates Phase 2 EMERGE Study of Vopratelimab in Combination with Ipilimumab in Patients with Non-Small Cell Lung Cancer or Urothelial Cancer
17.06.2019
Avelas Biosciences Selected as a 2019 Showcase Company by MedTech Innovator
04.06.2019
Allena Pharmaceuticals Announces Interim Results from Study 206 of Reloxaliase in High Risk Patients with Advanced Oxalate Disorders
03.06.2019
TransMedics Announces the Second FDA PMA Approval for its OCS Lung System, Allowing Access to a Larger Pool of Donor Lungs that are Currently Seldomly Utilized for Transplantation Due to Limitations of Cold Storage
14.05.2019
Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Superior Dose-Related Target Engagement Activity to PTG-100 in Single Ascending Dose Phase 1 Study
08.05.2019
Protagonist Therapeutics Expands PTG-200 Collaboration Agreement with Janssen to Include Second Generation Oral IL-23 Receptor Antagonists
06.05.2019
TransMedics Announces Closing of its Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
01.05.2019
TransMedics Announces Pricing of Upsized Initial Public Offering
08.04.2019
Neon Therapeutics Announces Completion of Enrollment in Phase 1b NT-002 Clinical Trial of NEO-PV-01 in Metastatic Non-Small Cell Lung Cancer
04.04.2019
Final Results from The Heart EXPAND Pivotal Trial Using the Organ Care System (OCS) Heart Technology Presented at the 2019 Annual Meeting of The International Society for Heart and Lung Transplantation in Orlando
03.04.2019
Jounce Therapeutics Presents Preclinical Data from JTX-8064 Program at the 2019 American Association for Cancer Research (AACR) Annual Meeting
02.04.2019
Jounce Therapeutics Reports Improved PFS and OS Associated with Vopratelimab (JTX-2011) Treatment Emergent Biomarker at the 2019 American Association for Cancer Research (AACR) Annual Meeting
31.03.2019
Neon Therapeutics Presents Updated Data from Ongoing Phase 1b NT-001 Clinical Trial of Personal Neoantigen Vaccine NEO-PV-01 at AACR 2019 Annual Meeting
28.03.2019
Proteon Therapeutics Announces Top-Line Results From Phase 3 PATENCY-2 Clinical Trial of Vonapanitase in Radiocephalic Arteriovenous Fistulas
27.03.2019
Allena Pharmaceuticals Announces Agreement with Duke Clinical Research Institute for URIROX-2 Pivotal Phase 3 Trial
24.01.2019
Proteon Therapeutics Announces Publication of Results from Phase 3 PATENCY-1 Clinical Trial of Investigational Vonapanitase in Patients with Chronic Kidney Disease
09.01.2019
Protagonist Therapeutics Initiates Phase 2 Trial of Novel Hepcidin Mimetic PTG-300 for the Treatment of Patients with Beta Thalassemia
09.01.2019
Upcoming Events - 1Q 2019
04.01.2019
Allena Pharmaceuticals Announces Appointment of Louis Brenner, M.D. as Chief Executive Officer and Confirms Key Milestones for 2019
03.01.2019
Jounce Therapeutics Completed Enrollment in First Cohort of Phase 1 Clinical Trial with its PD-1 Inhibitor, JTX-4014
02.01.2019
Allena Pharmaceuticals Achieves Alignment with FDA on Phase 3 Program and Accelerated Approval Pathway for Reloxaliase in Enteric Hyperoxaluria
13.12.2018
Protagonist Therapeutics Initiates Phase 1 Trial of Oral, Gut-Restricted, Alpha-4-Beta-7 Integrin Antagonist PN-10943
06.12.2018
Neon Therapeutics and Apexigen Announce First Patient Dosed in Neon's NT-003 Phase 1b Combination Trial of NEO-PV-01 in Metastatic Melanoma
27.11.2018
Protagonist Therapeutics Announces New Development Candidate PN-10943 for the Treatment of Inflammatory Bowel Disease
10.11.2018
Jounce Therapeutics Presents Reverse Translational, Biomarker and Preclinical Data from ICOS Program at the Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting
09.11.2018
Neon Therapeutics Presents Updated Data at the Society for Immunotherapy of Cancer's 33rd Annual Meeting
07.11.2018
Neon Therapeutics Appoints Industry Veteran Robert Bazemore to its Board of Directors
06.11.2018
Protagonist Therapeutics Announces Completion of Phase 1 Clinical Trial of Oral IL-23 Receptor Antagonist PTG-200
22.10.2018
Protagonist Therapeutics Presents Clinical Data from the PROPEL Study of PTG-100 in Ulcerative Colitis at United European Gastroenterology Week
22.10.2018
Allena Pharmaceuticals Presents Preclinical Data Demonstrating Normalized Urine Uric Acid Excretion and Plasma Urate Reduction Following Treatment with ALLN-346
22.10.2018
Neon Therapeutics Presents Data from Ongoing Phase 1b NT-001 Clinical Trial at European Society for Medical Oncology 2018 Congress
01.10.2018
Neon Therapeutics Congratulates Founder James P. Allison, Ph.D., for 2018 Nobel Prize in Physiology or Medicine
01.10.2018
Jounce Therapeutics Founder Dr. James P. Allison Jointly Awarded 2018 Nobel Prize in Physiology or Medicine for the Discovery of Cancer Therapy by Inhibition of Negative Immune Regulation
27.09.2018
Protagonist Therapeutics Announces Fast Track Designation Granted by U.S. FDA to Hepcidin Mimetic PTG-300
06.09.2018
Protagonist Therapeutics Receives $1.45 Million SBIR Funding for the Development of PTG-300
06.08.2018
Protagonist Therapeutics Secures $22 Million Equity Financing
06.08.2018
Final Results from the Protagonist PROPEL Study Support Further Clinical Development of PTG-100 for the Treatment of Ulcerative Colitis
02.08.2018
Avelas Biosciences Initiates Period 2 of Phase 2 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery
23.07.2018
Allena Pharmaceuticals Announces First Patients Treated in Phase 2 Basket Study of ALLN-177 in Patients with Primary Hyperoxaluria or Enteric Hyperoxaluria and Advanced Chronic Kidney Disease
16.07.2018
enGene Appoints Veteran Life Sciences Executive Jason D. Hanson as Chief Executive Officer and President
29.06.2018
Neon Therapeutics Announces Closing of Initial Public Offering
19.06.2018

Allena Pharmaceuticals Completes Animal Proof-of-Concept Study for ALLN-346, Lead Product Candidate for Hyperuricemia in the Setting of Advanced Chronic Kidney Disease
18.06.2018

Protagonist Announces Phase 1 and Pre-clinical Data on Hepcidin Mimetic PTG-300 Presented at European Hematology Association Annual Meeting
02.06.2018

Jounce Therapeutics Presents Preliminary Efficacy Data from Ongoing Phase 1/2 ICONIC Trial of JTX-2011 in Patients with Advanced Cancers
08.05.2018

Neon Therapeutics Announces First Patient Treated in Clinical Trial Evaluating Personal Cancer Vaccine NEO-PV-01 in Combination with KEYTRUDA® (pembrolizumab) and Chemotherapy
12.04.2018

TransMedics Inc., a Portfolio company of Pharmstandard International S.A., Receives FDA Pre-Market Approval (PMA) for its OCS™ Lung System for Near-Physiologic Preservation and Assessment of Lungs for Transplantation
12.04.2018

The Results of the OCS™ Lung INSPIRE Trial Published in The Lancet Respiratory Medicine Journal
06.03.2018

Allena Pharmaceuticals Initiates First Phase 3 Trial for ALLN-177 in Patients with Enteric Hyperoxaluria
05.03.2018

Proteon Therapeutics Completes Enrollment in PATENCY-2, Phase 3 Clinical Trial of Investigational Vonapanitase
04.01.2018

Avelas Biosciences Completes Period 1 Patient Enrollment in Phase 2 Study of AVB-620 in Women with Primary, Nonrecurrent Breast Cancer Undergoing Surgery
14.12.2017

Protagonist Therapeutics Announces Final Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300
14.12.2017

Jounce Therapeutics Added to NASDAQ Biotechnology Index
07.12.2017

Neon Therapeutics Announces Clinical Trial Collaboration with Merck
09.11.2017

Protagonist Therapeutics Initiates Phase 1 Trial of Oral Peptide IL-23 Receptor Antagonist, PTG-200
01.11.2017

Allena Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
31.10.2017

enGene named Company of the Year by BIOTECanada
04.10.2017

Neon Therapeutics Enters License Agreement with the Netherlands Cancer Institute for Neoantigen-based T Cell Therapeutics
26.09.2017

Newly Published Data Supports Avelas Biosciences' Investigational Ratiometric Activatable Fluorescent Peptide AVB-620 in Intraoperative Tumor Detection
20.09.2017

Protagonist Therapeutics Announces Preliminary Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300
14.09.2017

Avelas Biosciences' AVB-620 Shows Sensitive In Vivo Visualization of Breast Cancer in Journal Publication
15.08.2017

Jounce Therapeutics Names Hugh Cole as Chief Business Officer and Head of Corporate Development
03.08.2017

Avelas Biosciences Doses First Patient in Phase 2 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery
27.07.2017

European commission grants orphan drug designation to Allena Pharmaceuticals' investigational therapy for the treatment of primary hyperoxaluria
25.07.2017

Neon Therapeutics and Apexigen Announce Immuno-Oncology Clinical Trial Collaboration
13.07.2017

FDA grants orphan drug designation to Allena Pharmaceuticals' investigational therapy for the treatment of primary hyperoxaluria
10.07.2017

CRISPR Therapeutics and Neon Therapeutics Enter Research Collaboration
05.07.2017

Initial Results from Dana-Farber Cancer Institute Personalized Neoantigen Vaccine Published in Nature
30.05.2017

Protagonist Therapeutics Enters into Worldwide Agreement with Janssen to Co-Develop and Commercialize PTG-200 for Inflammatory Bowel Disease
21.01.2017

Jounce Therapeutics, Announced Pricing of Initial Public Offering
18.08.2016

Protagonist Therapeutics, has successfully completed Initial Public Offering
20.07.2016

Jounce Therapeutics, Signed a Major Collaboration Deal with Celgene to Develop Next-Generation Immuno-oncology Therapies
10.12.2015

Allena Pharmaceuticals, Inc. raises $53M from a strong syndicate of investors, including Pharmstandard International S.A.
25.11.2014

Proteon Therapeutics Goes Public on NASDAQ
26.05.2013

Aquinox Awarded by Canadian Biotech Industry Organization
18.12.2019
Neon Therapeutics Submits European Clinical Trial Authorization Application for Personal Neoantigen-Targeted T Cell Therapy NEO-PTC-01
04.12.2019
TransMedics' Organ Care System (OCS™) Technology Used in First U.S. Adult Human Heart Transplants From DCD Donors
04.12.2019
Allena Pharmaceuticals Provides Updates on Reloxaliase Development Program and Corporate Activities
03.12.2019
Protagonist Therapeutics Announces Preliminary Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Transfusion Dependent Beta-Thalassemia
22.11.2019
Avelas Welcomes Susan Stimson to its Board of Directors
20.11.2019
Neon Therapeutics Announces New Strategic Focus on Novel T Cell Programs
08.11.2019
Neon Therapeutics Announces Updated Data Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting
07.11.2019
Allena Pharmaceuticals Reports Positive Reloxaliase Topline Results from URIROX-1 Trial and from Study 206
06.11.2019
Protagonist Therapeutics Announces First Patient Dosed in a Phase 2 Study of Oral IL-23 Receptor Antagonist PTG-200 (JNJ-67864238) in the Treatment of Crohn's Disease
31.10.2019
Protagonist Therapeutics Secures Debt Facility for up to $50 Million
30.10.2019
Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Polycythemia Vera
23.09.2019
Proteon Therapeutics and ArTara Therapeutics Agree to Combine
17.09.2019
Jounce Therapeutics Names Jacquelyn Fahey Sandell as Chief Legal Officer and Corporate Secretary
16.09.2019
Allena Pharmaceuticals Completes Enrollment in Pivotal Phase 3 URIROX-1 Trial Evaluating Reloxaliase in Patients with Enteric Hyperoxaluria
05.09.2019
Neon Therapeutics Announces Publication in Immunity of Novel Approach to Predict MHC Class II Cancer-Specific Neoantigens
01.08.2019
Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Sustained Dose-Related Target Engagement Activity in a Multiple Ascending Dose Phase 1 Study
30.07.2019
TransMedics Announces Successful Long Distance Retrieval and Transplantation of Donor Lungs from Hawaii Using Organ Care System
23.07.2019
Jounce Therapeutics Announces Update on Strategic Collaboration with Celgene Corporation
15.07.2019
Neon Therapeutics' Personal Neoantigen Vaccine Study Demonstrates Prolonged Progression-Free Survival in Advanced or Metastatic Melanoma, Non-Small Cell Lung and Bladder Cancers
27.06.2019
Allena Pharmaceuticals Announces $10.0 Million Registered Direct Offering of Common Stock
18.06.2019
Jounce Therapeutics Initiates Phase 2 EMERGE Study of Vopratelimab in Combination with Ipilimumab in Patients with Non-Small Cell Lung Cancer or Urothelial Cancer
17.06.2019
Avelas Biosciences Selected as a 2019 Showcase Company by MedTech Innovator
04.06.2019
Allena Pharmaceuticals Announces Interim Results from Study 206 of Reloxaliase in High Risk Patients with Advanced Oxalate Disorders
03.06.2019
TransMedics Announces the Second FDA PMA Approval for its OCS Lung System, Allowing Access to a Larger Pool of Donor Lungs that are Currently Seldomly Utilized for Transplantation Due to Limitations of Cold Storage
14.05.2019
Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Superior Dose-Related Target Engagement Activity to PTG-100 in Single Ascending Dose Phase 1 Study
08.05.2019
Protagonist Therapeutics Expands PTG-200 Collaboration Agreement with Janssen to Include Second Generation Oral IL-23 Receptor Antagonists
06.05.2019
TransMedics Announces Closing of its Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
01.05.2019
TransMedics Announces Pricing of Upsized Initial Public Offering
08.04.2019
Neon Therapeutics Announces Completion of Enrollment in Phase 1b NT-002 Clinical Trial of NEO-PV-01 in Metastatic Non-Small Cell Lung Cancer
04.04.2019
Final Results from The Heart EXPAND Pivotal Trial Using the Organ Care System (OCS) Heart Technology Presented at the 2019 Annual Meeting of The International Society for Heart and Lung Transplantation in Orlando
03.04.2019
Jounce Therapeutics Presents Preclinical Data from JTX-8064 Program at the 2019 American Association for Cancer Research (AACR) Annual Meeting
02.04.2019
Jounce Therapeutics Reports Improved PFS and OS Associated with Vopratelimab (JTX-2011) Treatment Emergent Biomarker at the 2019 American Association for Cancer Research (AACR) Annual Meeting
31.03.2019
Neon Therapeutics Presents Updated Data from Ongoing Phase 1b NT-001 Clinical Trial of Personal Neoantigen Vaccine NEO-PV-01 at AACR 2019 Annual Meeting
28.03.2019
Proteon Therapeutics Announces Top-Line Results From Phase 3 PATENCY-2 Clinical Trial of Vonapanitase in Radiocephalic Arteriovenous Fistulas
27.03.2019
Allena Pharmaceuticals Announces Agreement with Duke Clinical Research Institute for URIROX-2 Pivotal Phase 3 Trial
24.01.2019
Proteon Therapeutics Announces Publication of Results from Phase 3 PATENCY-1 Clinical Trial of Investigational Vonapanitase in Patients with Chronic Kidney Disease
09.01.2019
Protagonist Therapeutics Initiates Phase 2 Trial of Novel Hepcidin Mimetic PTG-300 for the Treatment of Patients with Beta Thalassemia
09.01.2019
Upcoming Events - 1Q 2019
04.01.2019
Allena Pharmaceuticals Announces Appointment of Louis Brenner, M.D. as Chief Executive Officer and Confirms Key Milestones for 2019
03.01.2019
Jounce Therapeutics Completed Enrollment in First Cohort of Phase 1 Clinical Trial with its PD-1 Inhibitor, JTX-4014
02.01.2019
Allena Pharmaceuticals Achieves Alignment with FDA on Phase 3 Program and Accelerated Approval Pathway for Reloxaliase in Enteric Hyperoxaluria
13.12.2018
Protagonist Therapeutics Initiates Phase 1 Trial of Oral, Gut-Restricted, Alpha-4-Beta-7 Integrin Antagonist PN-10943
06.12.2018
Neon Therapeutics and Apexigen Announce First Patient Dosed in Neon's NT-003 Phase 1b Combination Trial of NEO-PV-01 in Metastatic Melanoma
27.11.2018
Protagonist Therapeutics Announces New Development Candidate PN-10943 for the Treatment of Inflammatory Bowel Disease
10.11.2018
Jounce Therapeutics Presents Reverse Translational, Biomarker and Preclinical Data from ICOS Program at the Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting
09.11.2018
Neon Therapeutics Presents Updated Data at the Society for Immunotherapy of Cancer's 33rd Annual Meeting
07.11.2018
Neon Therapeutics Appoints Industry Veteran Robert Bazemore to its Board of Directors
06.11.2018
Protagonist Therapeutics Announces Completion of Phase 1 Clinical Trial of Oral IL-23 Receptor Antagonist PTG-200
22.10.2018
Protagonist Therapeutics Presents Clinical Data from the PROPEL Study of PTG-100 in Ulcerative Colitis at United European Gastroenterology Week
22.10.2018
Allena Pharmaceuticals Presents Preclinical Data Demonstrating Normalized Urine Uric Acid Excretion and Plasma Urate Reduction Following Treatment with ALLN-346
22.10.2018
Neon Therapeutics Presents Data from Ongoing Phase 1b NT-001 Clinical Trial at European Society for Medical Oncology 2018 Congress
01.10.2018
Neon Therapeutics Congratulates Founder James P. Allison, Ph.D., for 2018 Nobel Prize in Physiology or Medicine
01.10.2018
Jounce Therapeutics Founder Dr. James P. Allison Jointly Awarded 2018 Nobel Prize in Physiology or Medicine for the Discovery of Cancer Therapy by Inhibition of Negative Immune Regulation
28.09.2018

Upcoming Events – 4Q 2018
27.09.2018
Protagonist Therapeutics Announces Fast Track Designation Granted by U.S. FDA to Hepcidin Mimetic PTG-300
06.09.2018
Protagonist Therapeutics Receives $1.45 Million SBIR Funding for the Development of PTG-300
06.08.2018
Protagonist Therapeutics Secures $22 Million Equity Financing
06.08.2018
Final Results from the Protagonist PROPEL Study Support Further Clinical Development of PTG-100 for the Treatment of Ulcerative Colitis
02.08.2018
Avelas Biosciences Initiates Period 2 of Phase 2 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery
23.07.2018
Allena Pharmaceuticals Announces First Patients Treated in Phase 2 Basket Study of ALLN-177 in Patients with Primary Hyperoxaluria or Enteric Hyperoxaluria and Advanced Chronic Kidney Disease
16.07.2018
enGene Appoints Veteran Life Sciences Executive Jason D. Hanson as Chief Executive Officer and President
29.06.2018
Neon Therapeutics Announces Closing of Initial Public Offering
19.06.2018

Allena Pharmaceuticals Completes Animal Proof-of-Concept Study for ALLN-346, Lead Product Candidate for Hyperuricemia in the Setting of Advanced Chronic Kidney Disease
18.06.2018

Protagonist Announces Phase 1 and Pre-clinical Data on Hepcidin Mimetic PTG-300 Presented at European Hematology Association Annual Meeting
02.06.2018

Jounce Therapeutics Presents Preliminary Efficacy Data from Ongoing Phase 1/2 ICONIC Trial of JTX-2011 in Patients with Advanced Cancers
08.05.2018

Neon Therapeutics Announces First Patient Treated in Clinical Trial Evaluating Personal Cancer Vaccine NEO-PV-01 in Combination with KEYTRUDA® (pembrolizumab) and Chemotherapy
12.04.2018

TransMedics Inc., a Portfolio company of Pharmstandard International S.A., Receives FDA Pre-Market Approval (PMA) for its OCS™ Lung System for Near-Physiologic Preservation and Assessment of Lungs for Transplantation
12.04.2018

The Results of the OCS™ Lung INSPIRE Trial Published in The Lancet Respiratory Medicine Journal
26.03.2018

Upcoming Events – 2Q 2018
06.03.2018

Allena Pharmaceuticals Initiates First Phase 3 Trial for ALLN-177 in Patients with Enteric Hyperoxaluria
05.03.2018

Proteon Therapeutics Completes Enrollment in PATENCY-2, Phase 3 Clinical Trial of Investigational Vonapanitase
04.01.2018

Avelas Biosciences Completes Period 1 Patient Enrollment in Phase 2 Study of AVB-620 in Women with Primary, Nonrecurrent Breast Cancer Undergoing Surgery
20.12.2017

Upcoming Events – 1Q 2018
14.12.2017

Protagonist Therapeutics Announces Final Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300
14.12.2017

Jounce Therapeutics Added to NASDAQ Biotechnology Index
07.12.2017

Neon Therapeutics Announces Clinical Trial Collaboration with Merck
07.12.2017

Pharmstandard International and Middleland Capital's VTC Innovation Fund Co-lead $8.5m Series B Financing of TearSolutions, Inc.
05.12.2017

Pharmstandard International Participated in Series B Extension Funding of Neon Therapeutics
09.11.2017

Protagonist Therapeutics Initiates Phase 1 Trial of Oral Peptide IL-23 Receptor Antagonist, PTG-200
01.11.2017

Allena Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
31.10.2017

enGene named Company of the Year by BIOTECanada
04.10.2017

Neon Therapeutics Enters License Agreement with the Netherlands Cancer Institute for Neoantigen-based T Cell Therapeutics
29.09.2017

Upcoming Events – 2017
26.09.2017

Newly Published Data Supports Avelas Biosciences' Investigational Ratiometric Activatable Fluorescent Peptide AVB-620 in Intraoperative Tumor Detection
20.09.2017

Protagonist Therapeutics Announces Preliminary Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300
14.09.2017

Avelas Biosciences' AVB-620 Shows Sensitive In Vivo Visualization of Breast Cancer in Journal Publication
15.08.2017

Jounce Therapeutics Names Hugh Cole as Chief Business Officer and Head of Corporate Development
03.08.2017

Our Portfolio Company, Proteon Therapeutics Announces Closing of $22 Million Convertible Preferred Stock Financing
27.07.2017

European commission grants orphan drug designation to Allena Pharmaceuticals' investigational therapy for the treatment of primary hyperoxaluria
25.07.2017

Neon Therapeutics and Apexigen Announce Immuno-Oncology Clinical Trial Collaboration
13.07.2017

FDA grants orphan drug designation to Allena Pharmaceuticals' investigational therapy for the treatment of primary hyperoxaluria
10.07.2017

CRISPR Therapeutics and Neon Therapeutics Enter Research Collaboration
05.07.2017

Initial Results from Dana-Farber Cancer Institute Personalized Neoantigen Vaccine Published in Nature
30.05.2017

Protagonist Therapeutics Enters into Worldwide Agreement with Janssen to Co-Develop and Commercialize PTG-200 for Inflammatory Bowel Disease
21.01.2017

Jounce Therapeutics, Announced Pricing of Initial Public Offering
18.08.2016

Protagonist Therapeutics, has successfully completed Initial Public Offering
20.07.2016

Jounce Therapeutics, Signed a Major Collaboration Deal with Celgene to Develop Next-Generation Immuno-oncology Therapies
10.12.2015

Allena Pharmaceuticals, Inc. raises $53M from a strong syndicate of investors, including Pharmstandard International S.A.
25.11.2014

Proteon Therapeutics Goes Public on NASDAQ
16.05.2014

Inbio Ventures Co-Leads Syndicated $45 Million Series D Investment in Proteon Therapeutics
30.08.2013

Inbio Ventures Represents Lead Investor in $42.5 Million Financing Round for Argos Therapeutics
12.08.2013

Inbio Ventures Joins the Syndicated $18 Million Investment in Protagonist Therapeutics
26.05.2013

Aquinox Awarded by Canadian Biotech Industry Organization
03.04.2013

Aquinox investment

Pharmstandard Ventures is looking for innovative drug discovery/development projects targeting the unmet medical needs or providing dramatic advantages over the competition globally
Contact Us